Regan J. Lauer - 15 Dec 2024 Form 4 Insider Report for ImmunityBio, Inc. (IBRX)

Role
Chief Accounting Officer
Signature
/s/ Jason Liljestrom, as Attorney-in-Fact
Issuer symbol
IBRX
Transactions as of
15 Dec 2024
Net transactions value
-$21,534
Form type
4
Filing time
16 Dec 2024, 19:36:51 UTC
Previous filing
26 Feb 2024
Next filing
12 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IBRX Common Stock Options Exercise $0 +21,031 +22% $0.000000 115,365 15 Dec 2024 Direct
transaction IBRX Common Stock Tax liability $21,534 -7,503 -6.5% $2.87 107,862 15 Dec 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IBRX Restricted Stock Units Options Exercise $0 -21,031 -100% $0.000000 0 15 Dec 2024 Common Stock 21,031 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On December 15, 2024, the Reporting Person's restricted stock units ("RSUs") vested. The closing price of Immunity Bio, Inc.'s common stock on December 13, 2024 was the settlement price used to calculate the shares withheld.
F2 Each RSU represents a contingent right to receive one share of ImmunityBio, Inc. common stock.
F3 Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through each applicable vesting date, the RSUs vested as follows: 1/3rd of the RSUs subject to the award vested June 15, 2023, 1/3rd of the RSUs subject to the award vested December 15, 2023, and 1/3rd of the RSUs subject to the award vested December 15, 2024 such that the award was fully vested on December 15, 2024.